1.54 USD
-0.02 (-1.28%)
1.55 USD
+0.01 (+0.65%)
ChartMill assigns a Buy % Consensus number of 49% to NGM. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 1.7. This target is 10.11% above the current price.
- NGM was analyzed by 11 analysts. The buy percentage consensus is at 49. So analysts seem to be rather neutral about NGM.
- In the last month the buy percentage fell by 26 points. So the trust of analysts is decreasing.
- NGM was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-12 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2024-02-28 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-11-22 | B. Riley Securities | Maintains | Buy -> Buy |
| 2023-05-03 | Citigroup | Initiate | Buy |
| 2023-03-30 | B. Riley Securities | Maintains | Buy |
| 2022-11-04 | Raymond James | Maintains | Outperform |
| 2022-10-18 | Cowen & Co. | Maintains | Outperform |
| 2022-10-18 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2022-10-18 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-17 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2022-10-17 | Jefferies | Downgrade | Buy -> Hold |
| 2022-10-07 | B. Riley Securities | Maintains | Buy |
| 2022-07-20 | Jefferies | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2021-11-05 | Raymond James | Maintains | Strong Buy |
| 2021-09-17 | BMO Capital | Maintains | Outperform |
| 2021-09-13 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2021-08-06 | Raymond James | Maintains | Outperform |
| 2021-05-24 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2021-03-05 | Chardan Capital | Maintains | Buy |
| 2021-03-05 | Raymond James | Maintains | Strong Buy |
NGM BIOPHARMACEUTICALS INC / NGM FAQ
What is the average price target for NGM BIOPHARMACEUTICALS INC (NGM) stock?
11 analysts have analysed NGM and the average price target is 1.7 USD. This implies a price increase of 10.11% is expected in the next year compared to the current price of 1.54.
What is the consensus rating for NGM stock?
The consensus rating for NGM BIOPHARMACEUTICALS INC (NGM) is 49.0909 / 100 . This indicates that analysts generally have a neutral outlook on the stock.